News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cenomed BioSciences Joins Forces with U.S. Army Medical Research Institute of Chemical Defense to Evaluate Therapeutics for Use in Chemical Defense



9/24/2007 12:11:35 PM

IRVINE, Calif.--(BUSINESS WIRE)--Cenomed BioSciences, LLC, a majority-owned subsidiary of Abraxis BioScience, Inc. (NASDAQ:ABBI), today announced that it has signed a three-year cooperative research and development agreement (CRADA) with the United States Army Medical Research Institute of Chemical Defense (USAMRICD) to evaluate Cenomed’s lead investigational compound CM-2,501 and other associated compounds, for the prevention of toxicities following exposure to chemical warfare agents. Cenomed’s compounds are being developed as a pre- and post-exposure therapy for military and civilian victims of a chemical nerve agent attack. Financial terms of the agreement were not disclosed.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES